Bionano Genomics Q2 2025: Key Contradictions in Strategy, Revenue Growth, and System Utilization

Instrument placement and rental program, return rate of new systems, VIA software adoption and utilization, revenue growth expectations, instrument placement and sales strategy are the key contradictions discussed in Bionano Genomics' latest 2025Q2 earnings call.



Strategic Shift and Revenue Growth:
- Bionano Genomics reported total revenue of $6.7 million for Q2 2025, a decrease of 13% year-over-year, but an increase of 16% year-over-year in non-GAAP gross margin to 52%.
- The strategic shift to focus on routine users and reduce new instrument sales positively impacted revenue and profitability.

Flowcell Sales and Utilization Growth:
- Bionano sold 7,233 flowcells in Q2 2025, reflecting a 17% increase compared to the previous year.
- Growth was driven by increased utilization within the existing customer base, particularly the routine OGM and VIA software users.

Operating Expense Reduction and Efficiency:
- Non-GAAP operating expenses decreased by 53% year-over-year to $8.8 million in Q2 2025.
- The reduction was achieved through cost management and significant headcount reduction of over 300 people since Q2 2023.

Optical Genome Mapping and Reimbursement Support:
- Bionano installed 7 new optical genome mapping systems and brought back 8 systems in Q2 2025, maintaining an installed base of 378 systems.
- The company is building support for OGM reimbursement through increasing publications and receiving the second Category I CPT code from the AMA.